Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s72, 2022. DOI: 10.25251/skin.6.supp.72. Disponível em: https://skin.dermsquared.com/skin/article/view/1829. Acesso em: 8 jun. 2025.